Intellia Therapeutics Posts $23M Q4 Revenue, Loss Narrows to $0.83 per Share
Intellia Therapeutics reported Q4 loss of $0.83 per share, beating the $0.99 estimate, while revenues surged 73.8% to $23 million, driven by Regeneron collaboration and a $9 million SparingVision termination payment. With $605.1 million cash on hand, the company expects funding into H2 2027 ahead of lonvo-z study data.
1. Q4 Earnings Beat
Intellia Therapeutics reported a Q4 loss of $0.83 per share, narrower than the $0.99 estimate and $1.27 year ago, with revenues of $23 million beating the $12 million forecast and up 73.8% year-over-year.
2. Expense Trends and Cash Position
Research and development expenses declined 24.1% to $88.7 million while general and administrative costs rose 2.2% to $33.1 million. Cash, cash equivalents and marketable securities stood at $605.1 million as of December 31, 2025, funding operations into the second half of 2027.
3. Lonvo-z HAE Program
Enrollment in the pivotal Phase III HAELO study for hereditary angioedema completed in September 2025. Top-line data are due by mid-2026 and a biologics license application is planned for the second half of 2026 ahead of a potential U.S. launch in early 2027.
4. Nex-z ATTR Development
The FDA lifted the clinical hold on the Phase III MAGNITUDE-2 study of nexiguran ziclumeran for ATTRv-PN, with enrollment expected to finish in the second half of 2026. Intellia continues discussions to resolve the hold on the cardiomyopathy cohort of the MAGNITUDE program.